Nextera at the BIO International Convention June 2024! Nextera is attending the BIO International Convention in San Diego June 3 – 6, 2024! Please get in touch if you would like to meet our CEO/CSO Geir Åge Løset and our Head of BD Francis Y. and learn more about our approach in engineered TCR-Like antibody guiding towards pHLA targets with transformational potential in autoimmunity and oncology! Schedule a meeting here: https://lnkd.in/eEDtKaAK #BIO2024 #Innovation #HealthInnovation #NetworkingEvent #Autoimmunity #Oncology #Biopharma #ScienceAndBusiness #SanDiego
Om oss
Nextera is a drug and target discovery company offering a unique and novel approach for improved therapeutic intervention in the major disease areas autoimmunity, chronic inflammatory disorders and cancer. Our approach is to modulate the disease at the core of the escalating immune cascade translating to disease-specific treatment without compromising systemic immunity. Our strategy is to discover new targets and develop cognate drugs together with partners. We want to address complex diseases and jointly develop therapies in major indications that today seem difficult to treat. It all starts and ends with the patient – focused onto to diseased tissue and the underlying immune repertoires, Nextera brings the unique ability to decipher clinical material with the outlook of subsequent intervention.
- Nettsted
-
http://www.nextera.no/
Ekstern lenke til Nextera AS
- Bransje
- Bioteknologisk forskning
- Bedriftsstørrelse
- 11–50 ansatte
- Hovedkontor
- Oslo
- Type
- Privateid selskap
- Grunnlagt
- 2009
Beliggenheter
-
Primær
Oslo Innovation Center
Gaustadalléen 21
Oslo, 0349, NO
Ansatte i Nextera AS
-
Anders Tuv
Managing Director Radforsk Invest
-
Sebastian Berge-Seidl
Group Lead Molecular Biology | Ph.D. in Molecular Biology
-
Hans Ivar Robinson
CEO and Founder of Birk Venture, Executive Chairman and Co-founder of Nextera, Chairman and Co-founder of Zelluna, Non-executive Director at Accession
-
Bent Jakobsen
Founder & Chief Executive Officer at Accession Therapeutics Limited
Oppdateringer
-
Nextera presenting at the 6th Annual Cell Engager Summit, Boston 23rd of May 2024 Harnessing the power of T cell immunity in the form of biologics holds tremendous potential in cancer immunotherapy. A new area of engineered guiding to pHLA with precision specificity and sensitivity beyond that of the natural T cell in the form of T cell engagers unlocks an untapped vast source of differentiated and potentially disease-specific drug targets in an accessible and affordable modality. The Nextera team - Francis Y., Mark Fife, Geir Åge Løset - are thrilled to join the 6th Annual Cell Engager Summit in Boston May 21 – 23, 2024 showcasing how our differentiated NextCore platform has the capacity to develop unique preclinical stage T cell engagers guided by rare, ultrasensitive TCR-Like antibodies towards pHLA class I with picomolar cancer killing potency of liquid and solid cancer in our CEO/CSO Geir Åge Løset presentation “Empowering antibodies to target pHLA through NextCore TCR-Like antibodies”. #6thCellEngagerSummit #cancerimmunitherapy #TCRLikeantibodies
-
Nextera will be at the BIO Partnering @JPM Week - see you in San Francisco January 8-12, 2024! #JPM2024 #immunotherapy #buisnessgrowth
-
Nextera AS la ut dette på nytt
⭐️Nextera on the road!⭐️ Educational days in London at the Hanson Wade Group Tumour Models Summit in London Discussing current challenges in the industry to better understand future needs in our efforts in advanced targeted immunotherapy @Nextera AS #tumourmodels #oncology #learning #FutureReady
-
⭐️Nextera on the road!⭐️ Educational days in London at the Hanson Wade Group Tumour Models Summit in London Discussing current challenges in the industry to better understand future needs in our efforts in advanced targeted immunotherapy @Nextera AS #tumourmodels #oncology #learning #FutureReady
-
We had an incredible time at PEGS Europe! 🌟 The past few days in Lisbon were filled with fantastic presentations, engaging discussions, and the pleasure of meeting some truly wonderful people. 🤝 I want to extend a big thank you to the organizers for putting together such an outstanding event. 👏 Lisbon, you were an amazing host city! Your rich history, vibrant culture, and breathtaking views provided the perfect backdrop for this remarkable experience. 🏰🌅 #pegseurope #lisbon #innovation #networking #learning #conference #Nextera
-
Cloned native T cell receptors (TCRs) offer a unique path to defined autologous or allogeneic TCR redirected cell therapy across diseases. Despite promising clinical evidence e.g. in cancer immunotherapy, the natural polyspecificity and affinity threshold of native TCRs are limiting in harnessing the full potential of e.g. next generation TCR-T both with respect to efficacy and safety. TCR refinement through engineering offers a solution to overcome this limitation. By combining the strengths of our NextCore pIX phage display platform with a novel cell display system, we have established a robust and scalable TCR engineering pipeline termed NextCore-TCR designed to optimize TCRs which offers a predictable route to improved and safe TCR redirected cell therapy with potency and specificity beyond native TCRs. Visit our poster A090 “Enhancing redirected TCR immunotherapy through optimized TCRs” at #PEGSEurope to learn more from our Group Lead Molecular Biology Sebastian Berge-Seidl in Lisbon, Portugal 14 – 16 November. #tcr #proteinengineering #immunotherapy #celltherapy
-
Nextera is attending #BIOEurope! Join us Munich, November 6–8, 2023 to request a partnering meeting. https://bit.ly/3Sm2CY8